Abattis Bioceuticals Corp.
ATTBF · OTC
9/30/2019 | 6/30/2019 | 3/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Market Cap | $11,452 | $18,138 | $19,763 | $33,144 |
| - Cash | $2,019 | $2,690 | $3,665 | $2,638 |
| + Debt | $1,569 | $1,487 | $0 | $0 |
| Enterprise Value | $11,002 | $16,936 | $16,098 | $30,507 |
| Revenue | $226 | $128 | $2 | $1 |
| % Growth | 77.1% | 5,778.2% | 238.1% | – |
| Gross Profit | $162 | $76 | $2 | $1 |
| % Margin | 71.7% | 59.8% | 100% | 100% |
| EBITDA | -$424 | -$769 | -$121 | -$1,582 |
| % Margin | -187.3% | -601.9% | -5,586.6% | -245,958.6% |
| Net Income | -$907 | -$736 | -$143 | -$1,257 |
| % Margin | -400.9% | -575.7% | -6,556.7% | -195,450.4% |
| EPS Diluted | -0.002 | -0.002 | -0 | -0.003 |
| % Growth | -26.7% | -400% | 89.3% | – |
| Operating Cash Flow | $3,935 | $7,498 | -$590 | -$1,431 |
| Capital Expenditures | -$5,037 | -$2 | -$17 | -$5 |
| Free Cash Flow | -$1,102 | $7,497 | -$607 | -$1,436 |